profit from every $100 of sales.
$0$100
Flora Growth
We have no price for Flora Growth since 2 March 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$7.21-10.99% today
-62.1% since Oct 9, 25
1-year low $6.231-year high $19.95
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Flora Growth vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Flora Growth | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Flora Growth's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- 1.2×
- 0.3×
- –
- –
- -208.3%
- -104.7%
- 0.0%
Profitability
- -0.1%
- -27.9%
- -378.0%
- -27.0%
- -28.5%
- -170.4%
- -353.1%
- -344.4%
- -31.0%
- 0.2%
Growth
- +12.7%
- –
- −70.4%
- –
- –
Financial health
- -0.1×
- 0.10
- 7.8%
- -71.0×
- 1.39
- 1.19
- 0.91
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 17%of 946
Bottom 10%of 872
Top 45%of 867
What analysts expect
- Average price target
- $185.00
- Range
- $30.00 – $340.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Nov 5, 2025 | -4.93 | -2.13 | −131.5% |
| Aug 1, 2025 | -4.30 | -2.34 | −83.8% |
| May 13, 2025 | -1.56 | -0.39 | −300.0% |
| Mar 24, 2025 | -16.41 | -0.11 | −14,818.2% |
| Nov 13, 2024 | -9.38 | -3.52 | −166.5% |
| Aug 12, 2024 | -8.59 | -1.95 | −340.5% |
| May 14, 2024 | -10.94 | -8.59 | −27.4% |
| Mar 29, 2024 | -0.17 | -0.07 | −142.9% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
54No pass
Philip Fisher
40No pass
Peter Lynch
49No pass
Joel Greenblatt
0No pass
Charlie Munger
38No pass
Terry Smith
40No pass
Questions about Flora Growth
Is Flora Growth a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Flora Growth AI analysis
What does Flora Growth do?
Flora Growth Corp., along with its various subsidiaries, operates as a global enterprise specializing in the cultivation, processing, and advancement of medicinal cannabis and its derived products. It is in Drug Manufacturers - Specialty & Generic.
Does Flora Growth pay a dividend?
No. Flora Growth does not pay a dividend at the moment.
Is Flora Growth stock halal?
No. Flora Growth does not pass our halal screen: its debt is 1,208% of its market value, at or above the 33% limit. How we check
Who are Flora Growth's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Flora Growth's.
Prices: daily closes to Mar 2, 2026. Fundamentals: company reports via invest-like data.